Enara Bio Unveils DARKFOX Dark Antigen for Solid Tumor Immunotherapy at SITC 2025
核心洞察
Enara Bio (搜索) will present DARKFOX (搜索), a novel cancer (搜索)-specific dark antigen derived from an alternative open reading frame of FOXM1 (搜索), at the Society for Immunotherapy of Cancer meeting in November 2025.
The company has developed a bispecific T cell engager (搜索) targeting DARKFOX (搜索) that shows significant therapeutic potential for treating solid tumors (搜索) expressing this previously undiscovered antigen.
DARKFOX (搜索) represents a breakthrough in targeting genomic "dark matter" to identify cancer (搜索)-specific antigens that are highly prevalent and homogeneously expressed across solid tumors (搜索).
Enara Bio (搜索), a biopharmaceutical company pioneering the discovery of novel Dark Antigens and the development of bispecific T cell engagers for solid tumors (搜索), will present groundbreaking research on DARKFOX (搜索), a newly discovered cancer (搜索)-specific dark antigen, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 5-9, 2025, in National Harbor, Maryland.
Novel Dark Antigen Discovery
DARKFOX (搜索) represents a significant advancement in cancer (搜索) immunotherapy, identified as a novel alternative open reading frame of FOXM1 (搜索) that serves as an attractive cancer antigen for peptide-HLA targeting immunotherapy. The antigen was discovered through Enara Bio (搜索)'s proprietary EDAPT platform, which enables the identification of cancer-specific antigens from previously uncharted genomic "dark matter."
Joe Dukes, Chief Scientific Officer at Enara Bio (搜索), will deliver an oral presentation titled "Discovery and validation of DARKFOX (搜索), a novel alternative open reading frame of FOXM1 (搜索) that is an attractive cancer (搜索) antigen for peptide-HLA targeting immunotherapy" during the concurrent session "The Dark Genome: Making Cryptic Epitopes Actionable" on Saturday, November 8th at 4:35 PM ET.
Bispecific T Cell Engager Development
The company has developed a novel bispecific T cell engager (搜索) specifically designed to target solid tumors (搜索) expressing DARKFOX (搜索). This therapeutic approach represents a potent immunotherapy strategy that leverages the company's proprietary EnTiCE platform for developing bispecific T cell engagers against Dark Antigen targets that are highly prevalent and homogeneously expressed across solid tumors.
A second presentation will showcase this bispecific T cell engager (搜索) through a poster session on Friday, November 7th, focusing on "A novel bispecific T cell engager for the treatment of solid tumors (搜索) that express DARKFOX (搜索), a previously undiscovered antigen derived from an alternative open reading frame of FOXM1 (搜索)."
Platform Technology and Strategic Partnerships
Enara Bio (搜索)'s approach centers on illuminating Dark Antigen and T-cell biology to develop cancer (搜索) immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors (搜索). The company's EDAPT platform has generated a growing library of Dark Antigens that address the critical need for novel, cancer-specific targets in solid tumors.
The company has established a strategic partnership with Boehringer Ingelheim, which is combining multiple licensed Dark Antigens to create novel immunotherapies. This collaboration underscores the commercial potential and therapeutic value of Enara Bio (搜索)'s dark antigen discovery platform.
Investment and Corporate Backing
Based in Oxford, UK, Enara Bio (搜索) is supported by a strong syndicate of life science investors including RA Capital (搜索), Pfizer Ventures (搜索), M Ventures (搜索), Samsara BioCapital, SV Health Investors, and the Francis Crick Institute. This robust financial backing reflects confidence in the company's innovative approach to cancer (搜索) immunotherapy and its potential to address unmet medical needs in solid tumor treatment.